Stocks › BIOA
BioAge Labs, Inc.
BIOA·Nasdaq·
United States·USD
United States·USD$6.29
-0.07 (-1.10%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BIOA
BioAge Labs, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BIOAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BIOA by members of U.S. Congress · 4 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Sale $1,001 - $15,000 |
Jul 13, 2016 | Jun 9, 2016 | Filing ↗ |
| Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 20, 2014 | Oct 9, 2014 | Filing ↗ |
| Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 20, 2014 | Oct 10, 2014 | Filing ↗ |
| Suzan K. DelBeneHouse · D · WA |
BIOABioAge Labs, Inc. · Stock |
Purchase $15,001 - $50,000 |
Aug 17, 2014 | Jul 24, 2014 | Filing ↗ |
Whale Activity
Position changes in BIOA reported for 2026-06-30 by 9 tracked institutional filers
- Increased6
- New1
- Held0
- Decreased1
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 2.8M | $69.8M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $37.8M | increased |
| D. E. Shaw & Co., Inc. | 742.8K | $18.2M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 410.2K | $10.1M | increased |
| MILLENNIUM MANAGEMENT LLC | 222.6K | $5.5M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 165.7K | $4.1M | increased |
| CITADEL ADVISORS LLC | 78.4K | $1.9M | new |
| TWO SIGMA INVESTMENTS, LP | 61.4K | $1.5M | increased |
| Stonepine Capital Management, LLC | 20.0K | $490K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BIOA insiders, by quarter · Form 4
Recent Insider Transactions
109 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Barton ShanePrincipal Accounting Officer | Sale | −20.2K | $25.19 | $509K | Jun 30, 2026 | Form 4 ↗ |
| Barton ShanePrincipal Accounting Officer | Sale | −42.4K | $25.21 | $1.1M | Jun 29, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | Apr 23, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −8,820 | $17.81 | $157K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +3,383 | $6.57 | $22K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +5,437 | $4.11 | $22K | Apr 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −7,433 | $20.30 | $151K | Mar 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +2,000 | $6.57 | $13K | Mar 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +5,433 | $4.11 | $22K | Mar 2, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | Mar 1, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Sale | −7,433 | $18.75 | $139K | Feb 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +2,000 | $6.57 | $13K | Feb 2, 2026 | Form 4 ↗ |
| RUBIN PAUL DChief Medical Officer | Option exercise | +5,433 | $4.11 | $22K | Feb 2, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,541 | $4.38 | $16K | Feb 1, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Option exercise | +3,542 | $4.38 | $16K | Jan 16, 2026 | Form 4 ↗ |
| Fortney KristenChief Executive Officer · Director | Sale | −233.1K | $18.12 | $4.2M | Jan 13, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Sale | −1,923 | $21.08 | $41K | Jan 13, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Sale | −11.7K | $20.54 | $240K | Jan 13, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Sale | −4,440 | $19.45 | $86K | Jan 13, 2026 | Form 4 ↗ |
| GOLDSTEIN DOV A MDChief Financial Officer | Sale | −8,974 | $18.43 | $165K | Jan 13, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BIOA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $28.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 915.6K | $22.4M | 0.03% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 368.0K | $9.0M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 296.8K | $7.3M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 262.2K | $6.4M | 1.50% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 223.3K | $5.5M | 0.06% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF Fidelity Covington Trust | 171.4K | $4.2M | 0.07% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 385.0K | $3.5M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 118.1K | $2.9M | 0.19% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 155.5K | $2.7M | 0.01% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list BIOA's shares (CUSIP 09077V100), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Bihua ChenSCHEDULE 13G/A · passive (13G) · 2.4M shares5.4%
Aug 14, 2026 · ↗ - Cormorant Asset Management, LPSCHEDULE 13G/A · passive (13G) · 2.4M shares5.4%
Aug 14, 2026 · ↗ - Vinod KhoslaSCHEDULE 13G/A · passive (13G) · 1.8M shares4.0%
May 15, 2026 · ↗ - VK Services, LLCSCHEDULE 13G/A · passive (13G) · 1.8M shares4.0%
May 15, 2026 · ↗ - Khosla Ventures Opportunity Associates I, LLCSCHEDULE 13G/A · passive (13G) · 1.4M shares3.1%
May 15, 2026 · ↗ - Khosla Ventures Associates VI, LLCSCHEDULE 13G/A · passive (13G) · 437.2K shares1.0%
May 15, 2026 · ↗ - Khosla Ventures Opportunity I, LPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.1%
May 15, 2026 · ↗ - Khosla Ventures VI, LPSCHEDULE 13G/A · passive (13G) · 437.2K shares1.0%
May 15, 2026 · ↗ - Bihua ChenSCHEDULE 13G/A · passive (13G) · 2.9M shares6.5%
May 15, 2026 · ↗ - Cormorant Asset Management, LPSCHEDULE 13G/A · passive (13G) · 2.9M shares6.5%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming BioAge Labs, Inc. as client
No lobbying filings found naming BioAge Labs, Inc. as the client.
Government Contracts
Federal awards to BioAge Labs, Inc. · USAspending
No federal contract awards found for BioAge Labs, Inc..
U.S. Patents
Recent USPTO applications naming BioAge Labs, Inc.
No USPTO patent applications found for BioAge Labs, Inc..
Annual Financials
From BIOA's 10-K filings · XBRL
No annual XBRL figures on record for BIOA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in BIOA's price history.
About BioAge Labs, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersEMERYVILLE, CA
IncorporatedDE
SEC CIK0001709941 ↗